International Congress on Hormonal Steroids and Hormones and Cancer

The role of vitamin D and retinoids in controlling prostate cancer progression

D M Peehl and D Feldman

Department of Urology, Stanford University School of Medicine, Stanford, California, USA

1Department of Medicine, Stanford University School of Medicine, Stanford, California, USA

(Requests for offprints should be addressed to D Peehl; Email: dpeehl@stanford.edu)

Abstract

Prostate cancer is a leading cause of cancer-related deaths in many countries. Premalignant lesions and invasive cancer occur more frequently in the prostate than in any other organ other than the skin. Yet, the incidence of clinically detected prostate cancer is much lower than the histopathological incidence. The slow growth of prostate cancer and the low incidence of clinically manifest disease in some geographical locations or racial/ethnic groups suggest that prostate cancer can be controlled, perhaps by dietary factors. Vitamin D and retinoids have emerged as leading candidates both to prevent and to treat prostate cancer. Many of the activities of these compounds, established from epidemiological studies, research with cell culture and animal models, and clinical trials, are consistent with tumor suppressor effects. However, retinoids may have additional tumor enhancer properties that balance or negate anti-cancer activity. This perhaps explains the overall lack of protective effects of vitamin A compounds against prostate cancer found in epidemiological studies, and the minimal efficacy of retinoids in clinical trials to treat prostate cancer. While current efforts focus on developing strategies to use vitamin D compounds to control prostate cancer, the possibility exists that prostate cancer cells may become resistant to tumor suppressor effects of vitamin D. Analyses of experimental model systems show that prostate cancer cells become less sensitive to vitamin D through loss of receptors or signaling molecules that mediate vitamin D’s actions, or through changes in metabolic enzymes that synthesize or degrade vitamin D compounds. The potential promise of exploiting vitamin D to control prostate cancer is tempered by the possibility that prostate cancer, perhaps even at early stages, may develop mechanisms to escape tumor suppressor activities of vitamin D and/or retinoids.

Endocrine-Related Cancer (2003) 10 131–140

Unique features of prostate cancer

Prostate cancer, perhaps more than any other type of cancer, has features that lend themselves to control of progression. Autopsy studies show that cancer begins to arise in the prostate as early as the 3rd decade of life (Sakr et al. 1993), yet most men are not diagnosed with clinically evident prostate cancer until they are in their 60s (Abbas & Scardino 1997). This fact shows that prostate cancer progresses slowly and therefore should offer a wide window of opportunity for control strategies. Another factor relevant to control is the large variation in the incidence of clinical detection and mortality from prostate cancer across countries and among racial or ethnic groups (Hsing et al. 2000). For example, an African-American male has about a 15 times greater chance of being diagnosed with prostate cancer than an age-matched Japanese male. However, the incidence of clinically unsuspected cancer in the prostate does not show such a large variation among different populations (Breslow et al. 1977). Overall, men over 50 have about a 40% chance of having cancer in the prostate, regardless of nationality, race or ethnicity. Therefore, the initiation of prostate cancer probably occurs somewhat similarly around the world as far as is known, but progression to a clinically detectable state differs. The discrepancy between the frequency of ‘latent’ and clinically manifest cancer is presumably due to some variation in factors that control progression.

An examination of the natural history of the histopathogenesis of prostate cancer also shows several points at which progression could be controlled. The initial event in the conversion of normal prostatic epithelium to cancer is considered to be the development of dysplasia, also known as prostatic intraepithelial neoplasia (PIN) (McNeal & Bostwick 1986). Dysplasia occurs very frequently in the prostate and first
appears in men in their 30s (Sak et al. 1993). Invasive prostate cancer has been observed emerging directly from dysplastic lesions (McNeal et al. 1991). This, then, is one point of potential control – if progression of normal epithelium to dysplasia could be prevented, then presumably the incidence of invasive prostate cancer would be decreased.

Well-differentiated invasive prostate cancer is classified as grade 3 in the widely used Gleason grading system (Gleason 1977). Cancer at this stage is seemingly curable. In a study of patients at Stanford University who underwent radical prostatectomy to treat prostate cancer, those who had cancer consisting only of grade 3 had a greater than 90% chance of no biochemical recurrence, defined as an increase in serum prostate-specific antigen (PSA), within 5 years of prostatectomy. If, however, grade 4 or 5 (poorly differentiated) cancer was present, then the rate of recurrence was directly proportional to the percentage of grade 4/5 cancer (Stamey et al. 1999, 2000). Therefore, another point of control would be prevention of progression of grade 3 cancer (curable) to grade 4 (not curable by surgery). Farther down the line, another point of control would be to prevent the progression of recurrent cancer that is responsive to androgen ablation therapy to androgen-independent cancer (Ahmed & Trump 2002). For the most part, it is only this final stage of prostate cancer that causes death.

Vitamin D compounds, and to a lesser extent retinoids, have emerged as leading candidates to control prostate cancer progression. A variety of review articles have discussed current information regarding the potential ability of vitamin D compounds (Miller 1998, Blutt & Weigel 1999, Konety et al. 1999, Feldman et al. 2000) or retinoids (Lotan 1996) to prevent or treat prostate cancer. The potential applications of these compounds are based on evidence from epidemiological findings, cell and animal studies, and clinical trials. While many properties of vitamin D compounds and retinoids are consistent with tumor suppressor activity, new findings suggest that prostate cancer cells may develop mechanisms to subvert inhibitory actions of vitamin D or retinoids.

**Epidemiology**

The first suggestion that vitamin D status might relate to prostate cancer risk came from epidemiological studies. Schwartz and Hulka (1990) calculated that mortality rates from prostate cancer in the US were inversely correlated with latitude and degree of ultraviolet (UV) irradiation. These investigators surmised that vitamin D deficiency was the factor that increased prostate cancer risk in geographical locations with low levels of UV, since UV is the principal factor mediating synthesis of vitamin D. Results from a prospective case-control study of vitamin D metabolite levels in sera collected in the San Francisco Bay area supported this hypothesis (Corder et al. 1993). Mean levels of the active circulating metabolite of vitamin D, 1,25-dihydroxyvitamin D$_1$ (1,25D), were significantly lower in cases than in controls. An association between serum levels of 1,25D and risk of prostate cancer was not, however, found in all subsequent studies (Braun et al. 1995, Gann et al. 1996, Nomura et al. 1998). It is perhaps noteworthy that while a correlation between prostate cancer risk and serum levels of 1,25D are not consistently noted, some studies instead found that low levels of the vitamin D premetabolite, 25-hydroxyvitamin D$_1$ (25D), increased risk of prostate cancer diagnosis or aggressiveness (Ahonen et al. 2000). This may be related to new information regarding local production of 1,25D from 25D in the prostate, which is discussed later in this article.

Despite the inconsistent findings regarding serum measurements of vitamin D metabolites and prostate cancer risk, additional epidemiological studies add support to the concept that inadequate vitamin D increases prostate cancer risk. Using a measure of solar radiation optimized for vitamin D production, Grant (2002) recently estimated premature cancer mortality in the US due to insufficient solar UV-B radiation (UVB). Approximately 1% of deaths caused by prostate cancer were calculated as premature due to inadequate exposure to UVB. Another reported finding, that high levels of dietary calcium are a significant risk factor for prostate cancer (Giovannucci et al. 1998), may be related to vitamin D in that high levels of serum calcium reduce renal production of 1,25D, the major source of circulating hormone.

In contrast to the generally supportive epidemiological findings for the role of vitamin D in diminishing prostate cancer risk, a comprehensive evaluation of the preventive potential of vitamin A concluded that there was little evidence that intake of vitamin A had any substantial preventive effects against any cancer, including cancer of the prostate (Vainio & Rautalahti 1999).

**Antiproliferative effects of vitamin D compounds or retinoids on prostate cells**

Building on epidemiological studies suggesting that vitamin D deficiency increases the risk of prostate cancer, investigators began to study the effects of vitamin D compounds on prostate cells to establish a mechanistic basis for the epidemiological correlations. It is now well established that vitamin D compounds inhibit the growth of normal prostatic epithelial cells, primary cultures of prostate cancer cells, and many prostate cancer cell lines (reviewed in Miller 1998, Blutt & Weigel 1999, Konety et al. 1999, Feldman et al. 2000). Growth suppression occurs via the induction of cell cycle arrest and/or apoptosis. Molecules involved in the signaling pathways initiated by vitamin D are not yet well-defined but are being elucidated. The cell cycle inhibitor p21$^{WAF1/CIP1}$ is sometimes but not always required for antiproliferative activity of vitamin D on prostate cells (Zhuang & Burnstein 1998, Moffatt et al. 2001), and the insulin-like
growth factor binding protein-3 (IGFBP-3) has been implicated in some types of prostate cells as a mediator of 1,25D action (Boyle et al. 2001, Sprenger et al. 2001). Studies with androgen-responsive prostate cancer cells show cross-talk between androgen and vitamin D signaling pathways, with upregulation of the androgen receptor by vitamin D mediating many of vitamin D’s actions in these cells (Zhao et al. 1999, 2000).

Similarly, retinoids also have antiproliferative effects on normal prostatic epithelial cells and primary cultures of prostate cancer cells (Peehl et al. 1993, Igawa et al. 1994, Liang et al. 1999, Pasquali et al. 1999) as well as on prostate cancer cell lines (Fong et al. 1993, de Vos et al. 1997, Pili et al. 2001). Like 1,25D, 9-cis-retinoic acid also upregulates the androgen receptor in some prostate cancer cell lines (Zhao et al. 1999). In addition to the actions of vitamin D compounds or retinoids as single agents, there are many examples of additive or synergistic antiproliferative effects of these agents in combination on prostate cells (Peehl et al. 1995, Blutt et al. 1997, Elstner et al. 1999). These interactions between vitamin D compounds and retinoids are, at least partially, mediated at the receptor level, as discussed below.

**Vitamin D and retinoids as differentiation agents**

Several lines of evidence also suggest differentiating effects of vitamin D compounds or retinoids on prostate cells, in addition to cell cycle arrest or apoptosis. Levels of keratins 8 and 18, expressed in the differentiated secretory cells of the luminal prostatic epithelium, are increased by retinoic acid in cultured prostatic epithelial cells (Peehl et al. 1993). Upregulation of tissue transglutaminase by retinoic acid in primary cultures of normal and malignant prostatic cells is also consistent with differentiating effects (Pasquali et al. 1999). PSA, another differentiation marker of prostatic epithelial cells, is increased in androgen-responsive prostate cancer cells by vitamin D compounds (Zhao et al. 1999) or retinoids (Fong et al. 1993). Further evidence of differentiation activity of vitamin D was noted in animal studies in which the epithelium of rats maintained on a vitamin D-supplemented diet exhibited greater histological differentiation than that of vitamin D-deficient rats (Konety et al. 1996).

**Antimetastatic activity of vitamin D and retinoids**

In addition to antiproliferative activities, vitamin D compounds and retinoids have properties consistent with antimetastatic behavior. Treatment of several androgen-independent prostate cancer cell lines in vitro decreased invasion, adhesion and migration to laminin, probably mediated by decreased expression of α,β integrins (Sung & Feldman 2000) and matrix metalloproteinases (MMP) -2 and -9 (Schwartz et al. 1997). These in vitro effects of vitamin D may be linked to antimetastatic activity observed in a xenograft model of rat prostate cancer (Lokeshwar et al. 1999).

Retinoids have also been shown to reduce adhesion, motility, invasion and expression of proteinases, particularly plasminogen activator, by prostate cells (Dahiya et al. 1994, Kim et al. 1995, Webber & Waghry 1995).

**Activities of retinoids that are inconsistent with tumor suppressor activity**

While the majority of effects of vitamin D compounds and retinoids on prostate cells are growth inhibitory, it is important to note that not all effects of retinoids on prostate cells are consistent with tumor suppressor activity. Antiproliferative activity of certain retinoids is dose-dependent, and in fact low doses may actually stimulate rather than inhibit growth of prostatic cells (Fong et al. 1993, Peehl et al. 1993, Jones et al. 1997). Other dose-dependent effects of retinoids were observed in organ cultures, in which retinoids either inhibited or increased androgen-induced prostate growth and branching morphogenesis (Aboseif et al. 1997). Some studies showed that retinoids may decrease, rather than increase, expression of the differentiation marker, PSA (Dahiya et al. 1994, Hsieh & Wu 1997). In other studies, retinoids increased rather than decreased proteinases associated with cellular invasion (Liu & Rabbani 1995). Furthermore, potent growth inhibitory activity of antagonists rather than agonists of retinoic acid receptors on prostate cancer cell lines as well as primary cultures of prostate cancer cells were reported (Hammond et al. 2001). These divergent activities of retinoids, some of which could be construed as tumor promoting rather than suppressive, may be relevant to the previously mentioned inability to demonstrate an association between consumption of vitamin A and decreased prostate cancer risk in epidemiological studies (Vainio & Rautalahti 1999).

**Chemopreventive activity of vitamin D and retinoids**

No completely satisfactory model system exists to test chemopreventive activity of experimental compounds against prostate cancer, but several avenues have been explored. In one approach, investigators fed rats a ‘Western diet’ with high fat and low calcium and vitamin D (Xue et al. 1999). These animals exhibited hyperproliferation of the epithelium of the dorsal prostate. Increased levels of calcium and vitamin D in the diet blocked this hyperproliferation. If hyperproliferation is considered to promote tumorigenesis, then this experiment provides evidence for potential antitumor activity of calcium and/or vitamin D. Another model used to test chemopreventive activity of vitamin D was the GyT-15
transgenic mouse model of androgen-independent prostate cancer. In these mice, the vitamin D analog, EB 1089, did not alter the onset of tumors driven by the expression of SV40-antigen in the basal cells of the prostatic epithelium, but did slow tumor growth (Perez-Stable et al. 2002).

Chemopreventive activity of retinoids in animal models of prostate cancer has also been shown. Dietary 9-cis-retinoic acid reduced the incidence of prostate cancer in rats treated with androgen and a carcinogen (McCormick et al. 1999), and decreased the development of PIN in Noble rats, which spontaneously develop prostate cancer (Christov et al. 2002).

Also relevant to chemoprevention strategies are the synergistic activities that vitamin D shows with other putative chemopreventive agents. For example, 1,25D synergistically inhibited the growth of human prostatic epithelial cells with genistein (Rao et al. 2002), the component in soy believed to have chemopreventive properties (Moyad 1999).

**Clinical activity**

The first clinical trial to evaluate the efficacy of vitamin D in treating prostate cancer was a small Phase II trial with 13 patients with hormone-refractory cancer (Osborn et al. 1995). No objective responses were seen in response to 1,25D, although serum PSA declined in some individuals. In another small study, seven patients with early recurrent cancer following radical prostatectomy or radiation therapy were treated with 1,25D (Gross et al. 1998). In all seven patients, the doubling-time of the rise in serum PSA declined during treatment, suggesting that 1,25D slowed tumor growth (using serum PSA as a surrogate marker for cancer volume). In a recent Phase I trial of an analog of vitamin D, 1-hydroxyvitamin D$_2$ (Hectoral), two of the patients with hormone-refractory disease had an objective response to Hectoral (> 50% reduction in serum PSA levels) (Liu et al. 2002). In all of these trials, hypercalcemia or hypercalciuria was the limiting toxicity. However, results of a recent Phase I trial show that pulse dosing of 1,25D permits substantial dose escalation with minimal toxicity (Beer et al. 2001). Other strategies to overcome toxicity yet retain therapeutic efficacy include development of less calcemic analogs of vitamin D, use of 1,25D at low levels in combination with other agents, or treatment with the vitamin D precursor, 25D. The latter approach relies on the conversion of 25D to the active metabolite, 1,25D, through enzymatic activity in the prostate, as discussed below.

Clinical efficacy of retinoids appears less promising than that of vitamin D compounds. Several retinoids have been tested in clinical trials against prostate cancer, but generally with minimal or no efficacy (Trump et al. 1997, Culine et al. 1999, Kelly et al. 2000, Shalev et al. 2000). Whether this is due to inherent therapeutic inactivity or to limitations due to toxicity needs to be further explored.

**Prostate cancer cells may become less or non-responsive to vitamin D or retinoids**

Many prostate cancer cells retain a normal response to 1,25D. For instance, the majority of cells cultured from primary adenocarcinomas of the prostate respond in a similar manner as normal cells to 1,25D (Peehl et al. 1994). Similarly, many established prostate cancer cell lines are responsive to 1,25D. Even cell lines representative of advanced prostate cancer, such as androgen-independent cell lines derived from the androgen-dependent cell line LNCaP, still are growth inhibited by vitamin D compounds (Perez-Stable et al. 2002, Yang et al. 2002). Treatment with 1,25D blocked formation of metastases in an experimental prostate cancer model (Lokeshwar et al. 1999), showing that vitamin D can effectively control even late stages of prostate cancer progression. However, some prostate cancer cell lines (Miller et al. 1995) and even a primary culture of prostate cancer cells that we recently identified (unpublished results) are resistant to growth inhibition by 1,25D. The existence of these unresponsive cell cultures raises the possibility that resistance to vitamin D may develop during progression of prostate cancer.

**Vitamin D and retinoid receptors**

Response of cells to 1,25D or retinoids is controlled at several levels. One is by the number and affinity of receptors. Both the vitamin D receptor (VDR) and retinoid receptors (RXRs and RARs) are members of the nuclear hormone receptor superfamily (Mangelsdorf et al. 1995). On the basis of ligand binding assays and Scatchard analyses, primary cultures of normal prostatic epithelial cells from the peripheral zone have about 35 fmole VDR per milligram protein with a $K_d$ of approximately $10^{-10}$ M (Peehl et al. 1994). Stromal cells cultured from the prostate have considerably fewer VDRs (Peehl et al. 1994), suggesting that epithelial cells are the primary target of vitamin D in the prostate. Ligand binding by VDRs has been measured in tissues, confirming that the prostate is a target organ of 1,25D.

The number of VDRs in primary cultures of prostatic cancer cells spans a fairly large range, but overall does not differ significantly from normal cells (Peehl et al. 1994). Some prostate cancer cell lines, however, have very low levels of VDR. Growth inhibition of these cancer cell lines by 1,25D is attenuated. Restoration of VDR to normal levels generally makes these cells responsive to growth inhibition by 1,25D, showing that response of cells to 1,25D depends, at least in part, on levels of VDR (Hedlund et al. 1996, Zhuang et al. 1997). Whether VDR may be absent or present at abnormally low levels in prostate cancer tissues is not known. Localization of VDR by immunohistochemistry in whole tissues can be problematic, and although a few studies
have shown that VDRs are present in the nuclei of epithelial cells in normal and malignant prostatic tissues (Kivineva et al. 1998, Krill et al. 2001), for full scale investigation of VDRs in prostatic adenocarcinomas has been published. However, one study suggested that VDR levels may decrease in the prostate after age 60 (Krill et al. 2001), causing speculation regarding a possible link between decreased VDR and increased incidence of prostate cancer with age. Studies of other types of cancers showed that loss of VDR had prognostic significance in colon cancer (Evans et al. 1998), so further evaluation of VDR in prostate cancer would be worthwhile.

Retinoid receptors are also lost in some prostate cancer cell lines. Depending on the type of receptor that is absent, cells can still retain responsiveness to certain types of retinoids with affinity for remaining receptors. For example, the prostate cancer cell line DU 145 is resistant to all trans-retinoic acid, but responsive to an RARγ-selective retinoid (Lu et al. 1999). DU 145 and PC-3 cells lack RARβ and therefore do not respond to RARβ-selective retinoids unless RARβ is restored (Campbell et al. 1998). Aberrant methylation of RARβ DNA was found in a significant number of prostate cancer specimens (Nakayama et al. 2001) and immunohistochemical labeling showed that RARβ and RXRβ were diminished in prostate cancer compared with normal epithelium (Kikugawa et al. 2000). Therefore, resistance to retinoids may indeed develop in prostate cancers through loss or decreased expression of receptors.

Many of the retinoid receptors function as heterodimers with RXR, as does VDR (Kliewer et al. 1992). Alterations in RXR in cancer cells would therefore affect both vitamin D and retinoid signaling pathways. Degradation of RXRs has been shown to influence the sensitivity of cells to the antiproliferative effects of 1,25D (Pruffer et al. 2002). The development of dysplasia in the prostates of mice with conditional disruption of RXRα (Huang et al. 2002) illustrates the potential impact that loss of retinoid receptors might have on development of premalignant precursors of cancer.

Alterations in molecular targets of vitamin D or retinoids

Abnormal activity or expression of molecules involved in signaling pathways triggered by 1,25D or retinoids may also attenuate cellular response to these factors. The retinoblastoma tumor suppressor gene (pRb) and the cell cycle inhibitor p21WAF-1/CIP-1 are implicated in growth-inhibitory activity of 1,25D. Cancer cells that have deleted or mutated pRb or p21WAF-1/CIP-1 are often less sensitive to 1,25D (Zhuang & Burnstein 1998). Expression of pRb (Mack et al. 1998) and p21WAF-1/CIP-1 (Cheng et al. 2000) is variable among prostate cancers, suggesting that cancers with low expression of these genes may not respond optimally to the growth suppressive effects of 1,25D.

In some prostate cancer cell lines, growth inhibition by 1,25D occurs not only due to cell cycle arrest but also due to induction of apoptosis. Genetic changes that occur in prostate cancer may circumvent this tumor suppressive activity of 1,25D. The prostate cancer cell line LNCaP, for instance, undergoes apoptosis when treated with 1,25D in conjunction with decreased expression of the anti-apoptotic protein bcl-2 (Blutt et al. 2000). LNCaP cells engineered to overexpress bcl-2, however, no longer died when treated with 1,25D (Blutt et al. 2000). Overexpression of bcl-2 may also inhibit induction of apoptosis in prostate cancer cells by retinoic acid (Gao et al. 1999). Overexpression of bcl-2 is common in advanced prostate cancer, especially when androgen-independent (McDonnell et al. 1992), and 1,25D or retinoids might therefore be less effective in controlling these cancers.

Oncogenic changes alter response to vitamin D or retinoids

As discussed previously, VDR acts as a heterodimer with RXR, mediating cross-talk between the vitamin D and retinoid signaling pathways. This interaction of VDR with RXR is related to synergistic or additive activity of 1,25D and retinoids on prostatic and other types of cells (Peehl et al. 1995, Zhao et al. 1999). Disruption of this heterodimer has an effect on both pathways. RXR degradation can cause resistance to both vitamin D and retinoids (Pruffer et al. 2002). Solomon et al. (1999) showed that transformation of keratinocytes with a ras oncogene disrupted VDR/RXR dimerization and made keratinocytes unresponsive to growth inhibition by 1,25D. These investigators further demonstrated that disruption of the heterodimer was due to ras activation of mitogen activated protein kinase (MAPK), which phosphorylated RXRα and prevented binding of RXRα to VDR. Cancers with oncogenic ras, which includes a small subset of prostate cancers (Konishi et al. 1997), might therefore be resistant to 1,25D.

Other oncogenic changes alter cellular responses to vitamin D compounds and/or retinoids. Prostatic epithelial cells immortalized with SV40 T-antigen became unresponsive to growth inhibition by 1,25D, despite retention of VDR (Gross et al. 1996). Loss of response to retinoic acid accompanied conversion of SV40-immortalized prostatic epithelial cells to malignancy by introduction of a ras oncogene (Peehl et al. 1999).

Metabolism of vitamin D and retinoids

Another element controlling activity of vitamin D or retinoids is metabolism. The P450 enzyme 25-hydroxyvitamin D-24-hydroxylase (24-OHase) initiates the degradation of 1,25D to inactive compounds. Basal levels of 24-OHase in cells are usually quite low, but are quickly upregulated by treatment with 1,25D. DU 145, a prostate cancer cell line
derived from a metastasis, exhibits exceptionally high levels of 24-OHase in response to 1,25D, such that this cell line is very unresponsive to growth inhibition by 1,25D. Treatment of DU 145 cells with liarozole, an inhibitor of P450 enzymes, blocks activity of 24-OHase and restores sensitivity of DU 145 cells to 1,25D (Ly et al. 1999). Whether abnormally high induction of 24-OHase, causing rapid degradation of 1,25D and therefore loss of activity, occurs in prostate tissue is unknown.

**Regulation of activity of vitamin D and retinoids at the prereceptor level**

The major site of synthesis of 1,25D is the kidney. In proximal tubule cells, the enzyme vitamin D 1α-hydroxylase (1α-OHase) adds an hydroxyl group to 25D, converting it to 1,25D. Only recently were extrarenal sites of production of 1,25D recognized. The prostate is one of these sites, and Schwartz et al. (1998) showed that primary cultures of normal prostatic epithelial cells had 1α-OHase activity and synthesized 1,25D when given 25D. Conversion of 25D to the active metabolite, 1,25D, by the action of 1α-OHase resulted in growth inhibition of normal prostatic epithelial cells by 25D (Barreto et al. 2000). Thus, local synthesis of 1,25D in the prostate is presumed to be of biological significance and perhaps is more relevant to the control of prostate cancer than are circulating levels of 1,25D. This may explain why low serum levels of 25D, but not 1,25D, were found to correlate with increased risk of prostate cancer in some epidemiological studies. If local production of 1,25D is more important to antitumor activity of vitamin D in the prostate than systemic production, then the availability of circulating levels of the precursor, 25D, would be more significant than circulating levels of 1,25D.

We verified that normal prostatic epithelial cells have 1α-OHase activity but found that 1α-OHase activity was significantly reduced in primary cultures of prostate cancer cells (Hsu et al. 2001) as it is in the prostate cancer cell lines LNCaP, PC-3 and DU 145 (Schwartz et al. 1998, Hsu et al. 2001). Decreased activity of 1α-OHase in primary cultures of cancer cells and in cell lines was confirmed by Whitlatch et al. (2002). Insufficient activity of 1α-OHase in cancer cells has significant consequences with regard to local tumor suppressor effects of vitamin D. While treatment of normal cells with 25D resulted in growth inhibition equivalent to that induced by 1,25D, 25D was much less growth inhibiting than 1,25D on cancer cells (Hsu et al. 2001). This differential effect of 25D on normal versus cancer cells is due to the ability of normal but not cancer cells to convert the precursor 25D to the active metabolite, 1,25D, by the action of 1α-OHase. Indeed, Whitlatch et al. (2002) showed that restoration of 1α-OHase activity in LNCaP cells restored the ability of 25D to inhibit growth. If tumor suppressive effects of vitamin D in the prostate are more dependent on locally produced 1,25D than on circulating levels of 1,25D, then loss of 1α-OHase activity could contribute to the ability of prostate cancer cells to escape growth control mechanisms of vitamin D.

It is noteworthy that retinoid metabolism is also abnormal in prostate cancer cells. The enzyme lecithin:retinol acyltransferase (LRAT) converts retinol to retinyl esters, the major storage form of vitamin A within cells. LRAT is greatly reduced in many types of cancer cell lines, including many derived from the prostate (Guo et al. 2002). When cultures of normal prostatic epithelial cells were analyzed, all expressed significant LRAT activity. In contrast, primary cultures from adenocarcinomas, like prostate cancer cell lines, had very low levels of LRAT (Guo et al. 2002). In the absence of LRAT, storage of internal retinol as retinyl esters is insufficient, and cells lack a pool of precursors to convert to the active metabolite, retinoic acid. This finding in cultured cells may explain the previous report that prostate cancer has up to eight times less retinoic acid than normal prostatic tissues (Pasquali et al. 1996), perhaps because of insufficient stores of retinol esters. Prostate cancer cells may therefore escape the tumor suppressor effects of retinoids in the same way that they appear to escape growth control of vitamin D, by losing the enzymes responsible for local production of active metabolites.

**Conclusions**

The potential ability of vitamin D and, to a lesser extent, retinoids, to control prostate cancer is based on an extensive and growing body of scientific evidence. Given the correlation between vitamin D deficiency and prostate cancer risk, and the fact that age is the strongest risk factor known for prostate cancer, it is noteworthy that hypovitaminosis D is epidemic among the elderly (Lips 2001). The effects of aging on vitamin D status are due to insufficient exposure to UV, diets insufficient in vitamin D, and decreased activity of enzymes that synthesize active metabolites of vitamin D (Halloran & Portale 1997). It is interesting to consider the effect that restoring vitamin D to normal levels in older men might have on the incidence of clinically detected prostate cancer.

The promise of vitamin D and/or retinoids to control prostate cancer is tempered by the sobering realization that an early event in the progression of prostate cancer may be to eliminate two major growth inhibitory/differentiating/tumor suppressor pathways by loss of enzymes that create the active metabolites of these compounds. If this is validated, then using premetabolites of vitamin D or retinoids to control prostate cancer would be less effective than using active compounds. Additional changes that may occur at later stages in prostate cancer development, such as loss of vitamin D or retinoid receptors and alterations in molecules involved in the signaling pathways of these compounds,
could make cancer cells less responsive even to active metabolites. Although such changes have been found in experimental models, whether these alterations occur in prostate cancer tissues and at what frequencies needs to be determined.

References


Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobbaugh B, Dreznik MK, Vogelman JH & Orentreich N 1993 Vitamin D and prostate cancer: a prediagnostic study with stored sera [see comments]. *Cancer Epidemiology, Biomarkers and Prevention* 2 467–472.


Feldman D, Zhao XY & Krishnan AV 2000 Vitamin D and prostate cancer [editorial; comment]. *Endocrinology* 141 5–9.


Endocrine-Related Cancer (2003) 10 131–140
Hedlund TE, Moffatt KA & Miller GJ 1996 Stable expression of

Guo X, Knudsen BS, Peehl DM, Ruiz A, Bok D, Rando RR, Rhim
JS, Nanus DM & Gudas LJ 2002 Retinol metabolism and
lecithin:retinol acyltransferase (LRAT) levels are reduced in
prostate human prostate cancer cells and tissue specimens.


Holloway BR & Portale AA 1997 Vitamin D metabolism: the
effects of aging. In Vitamin D, pp 541–554. Eds D Feldman, FH

Hammond LA, Van Krimks CH, Durham J, Tomkins SE, Burnett
RD, Jones EL, Chandraratna RA & Brown G 2001 Antagonists
of retinoic acid receptors (RARs) are potent growth inhibitors

Hedlund TE, Moffatt KA & Miller GJ 1996 Stable expression of
the nuclear vitamin D receptor in the human prostatic carcinoma
line JCA-1: evidence that the antiproliferative effects of
1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively
through the genomic signaling pathway. Endocrinology 137
1554–1561.

Hisch TC & Wu JM 1997 Effects of fenretinide (4-HPR) on
prostate LNCaP cell growth, apoptosis, and prostate-specific
gene expression. Prostate 33 97–104.

Hsing AW, Tsao L & Devesa SS 2000 International trends and
patterns of prostate cancer incidence and mortality. International

Hsu JY, Feldman D, McNeal JE & Peehl, DM 2001 Reduced
1alpha-hydroxylase activity in human prostate cancer cells
correlates with decreased susceptibility to 25-hydroxyvitamin

Huang J, Powell WC, Khodavirdi AC, Wu J, Makita T, Cardiff
RD, Cohen MB, Sucov HM & Roy-Burman P 2002 Prostatic
intraepithelial neoplasia in mice with conditional disruption of
the retinoid X receptor alpha allele in the prostate epithelium.


Igawa M, Tanabe T, Chodak GW & Rukstalis DB 1994
N-(4-hydroxyphenyl) retinamide induces cell cycle specific
growth inhibition in PC3 cells. Prostate 24 299–305.

Jones HE, Eaton CL, Barrow D, Duitkowsi C & Griffiths K 1997
Response of cell growth and retinoid acid receptor expression to
retinoid acid in neoplastic and non-neoplastic prostate cell lines.

Prostate 30 174–182.

Kelly WK, Osman I, Reuter VE, Curley T, Heston WD, Nanus
DM & Scher HI 2000 The development of biologic end points
in patients treated with differentiation agents: an experience of
retinoids in prostate cancer. Clinical Cancer Research 6 838–
846.

Kikugawa T, Tanji N, Miyazaki T & Yokoyama M 2000
Immunohistochemical study of the receptors for retinoid acid
in prostatic adenocarcinoma. Anticancer Research 20 3897–3902.

Kim JH, Tanabe T, Chodak GW & Rukstalis DB 1995 In vitro
anti-invasive effects of N-(4-hydroxyphenyl)-retinamide on
human prostatic adenocarcinoma. Anticancer Research 15 1429–
1434.

Kivineva M, Blauer M, Syvala H, Tamela T & Tsurohina P 1998
Localization of 1,25-dihydroxyvitamin D3 receptor (VDR)
expression in human prostate. Journal of Steroid Biochemistry
and Molecular Biology 66 121–127.

Kliewer SA, Umesono K, Mangelsdorf DJ & Evans RM 1992
Retinoid X receptor interacts with nuclear receptors in retinoid
acid, thyroid hormone and vitamin D3 signalling. Nature 355
446–449.

Konety BR, Schwartz GG, Acierno Jr JS, Becich MJ &
Getzenberg RH 1996 The role of vitamin D in normal prostate
growth and differentiation. Cell Growth and Differentiation 7
1563–1570.

Konecy BR, Johnson CS, Trump DL & Getzenberg RH 1999
Vitamin D in the prevention and treatment of prostate cancer.
Seminars in Urologic Oncology 17 77–84.

Koniishi N, Hiasa Y, Tsuzaki T, Tao M, Enomoto T & Miller GJ
1997 Comparison of ras activation in prostate carcinoma in

Getzenberg RH 2001 Expression patterns of vitamin D receptor
in human prostate. Journal of Cellular Biochemistry 82 566–
572.

Liang JY, Fontana FA, Rao JN, Ordonez JV, Dawson MJ, Shroot
B, Wilber JF & Feng P 1999 Synthetic retinoid CD437 induces
S-phase arrest and apoptosis in human prostate cancer cells
LNCaP and PC-3. Prostate 38 228–236.

Lips P 2001 Vitamin D deficiency and secondary
hyperparathyroidism in the elderly: consequences for bone loss
and fractures and therapeutic implications. Endocrine Reviews 22
477–501.

Liu DF & Rabbani SA 1995 Induction of urinary plasminogen
activator by retinoic acid results in increased invasiveness of

Liu G, Oettel K, Ripple G, Staab MJ, Horvath D, Alberti D,
Arzoumanian R, Marnocha R, Bruskewitz R, Mauzess R, Bishop
C, Bhattacharya A, Bailey H & Wilding G 2002 Phase I trial of
1alpha,25-dihydroxyvitamin D2(3) in patients with hormone refractory

Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuan
SH, Block NL & Binderup L 1999 Inhibition of prostate cancer
metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D
(calcitriol) and EB1089. Cancer Epidemiology, Biomarkers and
Prevention 8 241–248.

Lotan R 1996 Retinoids in cancer chemoprevention. FASEB
Journal 10 1031–1039.

Lu XF, Fanjul A, Picard N, Shroot B & Pfahl M 1999 A selective
retinoid with high activity against an androgen-resistant prostate

Ly LH, Zhao XY, Holloway L & Feldman D 1999 Liarozole acts
generically with 1alpha,25-dihydroxyvitamin D3 to inhibit
growth of DU 145 human prostate cancer cells by blocking

McCormick DL, Rao KV, Steele VE, Lueb LT, Kelloff GJ &
Bosland MC 1999 Chemoprevention of rat prostate
carcinogenesis by 9-cis-retinoic acid. Cancer Research 59
521–524.

McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung
LW, Hsich JT, Tu SM & Campbell ML 1992 Expression of the
protooncogene bel-2 in the prostate and its association with
emergence of androgen-independent prostate cancer. Cancer
Research 52 6940–6944.

Mack PC, Chi SG, Meyers FL, Stewart SL, deVerhe White RW &
Gumerlock PH 1998 Increased RB1 abnormalities in human
primary prostate cancer following combined androgen blockade.

Prostate 34 145–151.

McNeal JE & Bostwick DG 1986 Intraductal dysplasia: a
premalignant lesion of the prostate. Human Pathology 17 64–71.

Microcarcinoma in the prostate: its association with duct-acinar

Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G,


Moffatt KA, Johannes WU, Hedlund TE & Miller GJ 2001 Growth inhibitory effects of 1α,25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. _Cancer Research_ 61 7122–7129.


Stamey TA, Yemoto CM, McNeal JE, Sigal BM & Johnstone IM 2000 Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. _Journal of Urology_ 163 1155–1160.


Peehl and Feldman: Role of vitamin D and retinoids in prostate cancer


